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TRANSFORMING GROWTH FACTOR – BETA (TGFβ) STIMULATED
ISOFORM SPECIFIC ACTIVATION OF AKT2, VIA RAS MEDIATES
EPITHELIAL- MESENCHYMAL TRANSITION (EMT)
PRAVEEN CHANDER
ABSTRACT
TGF induces epithelial-mesenchymal transdifferentiation (EMT) accompanied
by cellular differentiation and migration. EMT has emerged as a fundamental
process governing embryonic development, adult tissue homeostasis and
metastatic progression. Our lab had earlier identified a post-transcriptional
pathway by which TGF modulates expression of EMT-specific proteins. It was
shown that heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) binds a
structural, 33 nucleotides (nt) TGF beta-activated translation (BAT) element in
the 3’-UTR of disabled-2 (Dab2) and interleukin-like EMT inducer (ILEI)
transcripts, and repress their translation. This inhibition is removed following
hnRNP E1 phosphorylation by activated Akt2. We now show that specific
activation of Akt2, and not Akt1, following TGF stimulation is Ras dependent
and we provide evidence which suggest that Ras mediates a complex formation
between activated TGFβ receptors and ShcA, which in turn potentiates the
complex in order to specifically recruit Akt2, and not Akt1.
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CHAPTER I
INTRODUCTION

1.1 A brief introduction to Transforming Growth Factor-beta (TGFβ)
Transforming Growth Factor-beta or TGFβ is a multifunctional cytokine. It
is secreted in a context-dependent and tissue specific manner by fibroblasts and
epithelial cells. In the 1970s, several individual peptide growth factors that could
transform nonmalignant cells to a ‘transformed’ phenotype were identified
(Sporn, 1999). Multiple rounds of purification and extraction from virally
transformed cells, initially used to identify the sarcoma growth factor (de Larco
and Todaro, 1978), identified two growth promoting peptides. These peptides
named transforming growth factor-alpha (TGFα) and transforming growth factorbeta (TGFβ) were important for promoting growth, on soft agar, of normal rat
kidney epithelial (NRK) cells (Roberts et al., 1981; Anzano et al., 1983; Roberts
et al., 1983). Transforming Growth Factor β was purified and characterized as a
25-kDa homodimer from human platelets and placenta, and bovine kidney
(Assoian et al., 1983; Frolik et al., 1983; Roberts et al., 1983).
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The TGFβ family members are constituted by structurally related peptides
characterized by a conserved set of cysteine residues (Kingsley, 1994;
Massague, 1998; Shi and Massague, 2003). With the identification and addition
of TGFβ2 and TGFβ3, two other distinct mammalian isoforms of TGFβ, this
superfamily currently comprises of 34 family members. The members of this
superfamily are also highly conserved in a wide variety of organisms like
Caenorhabditis elegans, Drosophila melanogaster, Xenopus laevis. Apart from
TGFβ, this superfamily also includes Bone Morphogenetic Proteins (BMPs),
Mullerian Inhibiting Substance (MIS), Growth and Differentiation Factor (GDF),
Activins and Inhibin (Massague, 1998).
In contrast to TGFβ’s original cellular growth and proliferative functions, it
was subsequently also implicated as a potential inhibitor of cell growth (Tucker et
al., 1984). Several new functions have been subsequently discovered and TGFβ
has been shown to be an important player in immune suppression, angiogenesis,
programmed cell death and cell proliferation. However, one of the most important
role of TGFβ is its role in promoting epithelial to mesenchymal transdifferentiation
(EMT), a precursor step during development and cancer metastasis (Pepper,
1997; Bakin et al., 2000; Akhurst and Derynck, 2001; Derynck et al., 2001;
Dennler et al., 2002; Moustakas et al., 2002; Roberts and Wakefield, 2003;
Lamouille and Derynck, 2007; Massague, 2008; Xu et al., 2009).

2

1.2. The TGFβ Signal Transduction
TGFβ family ligands first bind to the constitutively active TGFβ type II
serine/threonine kinase receptor (TβRII). TβRII then recruits the type I receptor
(TβRI) resulting in the formation of an oligomeric receptor complex (Yamashita et
al., 1994). The type II receptor, now a part of the oligomeric complex,
phosphorylates the type I receptor at a highly conserved 30 amino acid sequence
with a characteristic SGSGSG sequence (the GS domain). This GS domain lies
directly uptream of the kinase domain (Wrana et al., 1994a; Wrana et al., 1994b;
Wieser et al., 1995). This phosphorylation activates the type I receptor-kinase
through a conformational change.
Recently, the crystal structural basis for this sequential receptor assembly
process into a heterotetrameric complex was elucidated (Groppe et al., 2008). It
was earlier shown that TβRII binds the fingertip of the extended TGFβ3 ligand
structure (Hart et al., 2002), with a conserved N-terminal extension in TβRII
remaining disordered. In the active complex however, seven residues of this Nterminal complex become ordered giving rise to an active heterotetrameric
complex formation. A five-residue finger in TβRI additionally hydrogen bonds with
an aspartate in TβRII. This model thus explains the lack of avidity of TβRI to free
TGFβ ligand (Groppe et al., 2008; Massague, 2008). The activated TβRI
interacts with, and phosphorylates many downstream signal transduction
3

proteins. Downstream signals may broadly be transduced in either a Smaddependent (canonical) or Smad-independent (non-canonical) signaling pathway.
1.3. Regulation and Attenuation of TGFβ Signaling
TGFβ signaling is attenuated either by the inhibitory I-Smads or
ubiquitination and proteosomal degradation of downstream Smads. The I-Smads
compete for Smad2/3 binding sites on the activated TβRI thereby antagonizing
TGFβ signaling (Imamura et al., 1997; Hata et al., 1998; Nakao et al., 1997;
Ebisawa et al., 2001). Smad7 dephosphorylates activated TβRI by initiating
interactions with a GADD34 and protein phosphatase 1 complex (Shi et al.,
2004). Smad7 also recruits Smurf E3 ubiquitin ligase to type I receptor and
therefore aids in initiation of proteosomal degradation, thereby preventing
sustained TGFβ signaling (Lin et al., 2000). E3 ubiquitin ligases Smurf2 (Lin et
al., 2000) and Skp1-Cul1F-box protein (SCF) (Fukuchi et al., 2001), mediates the
degradation of Smad2 and Smad3 respectively. Additionally, Smad3 degradation
may also be through the carboxy terminus of Hsp70 interacting protein (CHIP)
(McDonough and Patterson, 2003) or a direct interaction with Hsp70 resulting in
TGFβ independent ubiquitination and degradation (Xin et al., 2005).
An additional level of regulation of TGFβ signaling is rendered by corepressors like Ski and SnoN. TGFβ stimulation potentiates Smad3 and SnoN
binding within the nucleus. This complex is then degraded by the anaphase
promoting complex (APC) or Smurf2 (Bonni et al., 2001; Stroschein et al., 1999).
Transcriptional induction SnoN upon TGFβ signaling, thus allows a negative
4

feedback control of TGFβ signaling (Stroschein et al., 2001). TGFβ signaling may
also be attenuated by disruption of the Smad complex or by recruiting histone
deacetylases such as the N-CoR complex, to the chromatin by SnoN and Ski
(Wu et al., 2002).
Finally, PPM1A a phosphatase responsible for dephosphorylating the
Smad complex was identified in TGFβ signal attenuation. The dephosphorylated
Smads recycle back into the cytoplasm to await the next round of signaling (Lin
et al., 2006). However, whether degradation of proteins or the modulation of the
protein through post-translational modifications plays the dominant role in
abrogating TGFβ signaling remains to be elucidated. It is likely that ubiquitin
mediated proteosomal degradation and dephosphorylation events function
cooperatively and in a redundant fashion to ensure rapid kinetics and tight control
of TGFβ signal attenuation.

5

Figure 1.1 Schematic representation of the TGFβ signaling cascade and its
regulation.
TGFβ binds to its cognate receptor initiating a signaling cascade. The activated
TGFβ receptor phosphorylate R-Smads (Smad3) which subsequently forms a
complex with Co-Smad (Smad4). The Smad3/4 complex translocates into the
nucleus to modulate the functions of TGFβ responsive genes. Smad7 and
ubiquitin mediated proteasomal degradation of Smad 3 negatively regulate TGFβ
signaling.
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1.4. TGFβ-Mediated Epithelial to Mesenchymal Transition (EMT)
In Epithelial-mesenchymal transition (EMT), cells switch from a polarized,
epithelial phenotype to a motile fibroblastic or mesenchymal phenotype. A
fundamental process during embryonic development EMT can be reactivated in a
variety of diseases like fibrosis and cancer (Derynck et al., 2001; Zavadil and
Bottinger, 2005; Bierie and Moses, 2006; Thiery and Sleeman, 2006; Massague,
2008). TGF is one of the growth factors implicated in EMT (Massague, 2008).
TGFβ signaling mediated EMT has been extensively implicated as a causative
agent for tumor initiation and progression. While, during early stages of
tumorigenesis TGFβ exerts an antiproliferative effect it functions as a tumor
promoter at later stages aiding metastatic progression through an autocrine
TGFβ loop (Bierie and Moses, 2006). Transgenic mice expressing a dominant
negative TβRII in the epidermis and mammary glands show aggressive tumor
formation and metastatic progression (Amendt et al., 1998). Susceptibility of
TGFβ-mediated antiproliferative effects is absent in lung cancer (Yanagisawa et
al., 2000), head and neck squamous cell carcinoma (Garrigue-Antar et al., 1995),
prostate cancer (Park et al., 2000), gastric cancer (Myeroff et al., 1995; Kang et
al., 1999), colon cancer (Eppert et al., 1996; Markowitz et al., 2000), pancreatic
cancer (Goggins et al., 1998), and breast cancers (Lucke et al., 2001). Recently
7

it has been shown that the tumor suppressor Merlin and a trans-acting negative
regulator of signaling, Erbin fine regulates the context dependent response to
TGFβ signaling (Wilkes et al., 2009). It was shown that in fibroblasts, Merlin is
phosphorylated and subsequently inactivated by p21 activated kinase 2 (PAK2),
inducing growth and proliferation. PAK2 activity in epithelial cells promotes
apoptosis. To prevent antiproliferative effects in epithelial cells Merlin recruits
Erbin and disrupts activation and function of PAK2 (Wilkes et al., 2009).
Phosphorylation of Par6, a polarity protein by the activated receptor
complex has also been implicated in EMT. During metastasis, TGFβ promotes
epithelial to mesenchymal transition (EMT) (Derynck et al., 2001; Moustakas et
al., 2002; Zavadil and Bottinger, 2005), accompanied by a loss of cell-cell and
cell-matrix adhesion. These changes concomitantly convert a polarized epithelial
phenotype to an elongated mesenchymal phenotype (Zavadil and Bottinger,
2005; Thiery and Sleeman, 2006). The indispensable role of TGFβ-induced EMT
is emphasized during embryonic development (Trelstad et al., 1967; Massague,
2008). While EMT during development is largely spatially and temporally
regulated, EMT during advanced cancer progression may not reflect the order of
events observed during development (Larue and Bellacosa, 2005). EMT plays a
critical role in cancer cell motility, invasion and metastasis. Dissociation and
penetration of the basement membrane, which characteristize the developmental
of EMT are important steps in cancer metastasis.
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Many TGFβ non-canonical signaling pathways are involved in the
induction of EMT. Signaling through integrin β1 (Bhowmick et al., 2001),
p38MAPK (Bakin et al., 2002), phosphoinositide 3-kinase (PI3K) (Bakin et al.,
2000; Gotzmann et al., 2002; Kattla et al., 2008), Ras homologous (Rho) A
(Bhowmick et al., 2001; Janda et al., 2002), Jagged/Notch (Zavadil et al., 2004),
nuclear factor κβ (NF-κβ) (Huber et al., 2004) have all been shown to be required
for TGFβ-induced EMT. Untransformed murine NMuMG cells and mouse cortical
tubule (MCT) EMT, upon TGFβ treatment (Xie et al., 2004; Prunier and Howe,
2005) which can be blocked by the MEK inhibitor U0126 (Xie et al., 2004).
Canonical TGFβ signaling has also been implicated in EMT. TGFβ
signaling and Smad overexpression have a synergistic effect upon EMT
induction (Oft et al., 2002). Overexpression of Smad2 or Smad3, along with
Smad4, in human and mouse non-transformed cell lines enhanced TGFβinduced EMT. However, the expression of a dominant negative Smad2, Smad3,
or Smad4 blocked TGFβ-mediated EMT (Valcourt et al., 2005). In vivo, studies
using Smad3 knockout mice provide evidence for Smad3’s involvement in EMT.
Loss of Smad3 blocks injury-induced EMT in primary lens epithelial cells and fails
to induce EMT in primary tubular epithelial cells derived from Smad3-/- mouse
kidneys (Saika et al., 2004; Valcourt et al., 2005). Recently it was also shown
that TGFβ induced EMT only in control hepatocytes but not in Smad3 -/hepatocytes (Ju et al., 2006).

9

1.5. Significance of Dab2 and ILEI in TGF-mediated EMT: hnRNP E1 as the
Central Regulator
Cell lines NMuMG (Normal murine mammary gland epithelial) and EpRas
(mouse mammary epithelial cells EpH4, transformed with oncogenic Ras) are
two well established models for studying TGF-induced EMT (Miettinen et al.,
1994; Oft et al., 1996; Thuault et al., 2006). Studies using these in vitro models
identified two candidate EMT genes, Disabled-2 (Dab2) (Prunier and Howe,
2005) and FAM3C or interleukin like EMT inducer (ILEI) (Jechlinger et al., 2003;
Waerner et al., 2006). Dab2 identified as a putative tumor suppressor gene, also
modulates later stages of tumor progression by promoting EMT-dependent
metastasis (Mok et al., 1994; Prunier and Howe, 2005). Dab2 protein level is low
in many types of tumors (Bagadi et al., 2007). Several genetic studies
demonstrating a function for Dab2 in endodermal cell formation, organization,
and differentiation confirm its role in homeostatic balance of epithelial cell
differentiation, (Sheng et al., 2000; Morris et al., 2002; Yang et al., 2002).
The ILEI gene was initially identified as responsible for nonsyndromic
hearing loss locus 17 (DFNB17) (Greinwald et al., 1998). It was subsequently
placed as a member of the (FAM3A-D) gene family (Zhu et al., 2002). In
polysome profiling experiments where differential sedimentation was used to
separate heavy, ribosome-enriched, rapidly translating mRNAs (polysomes) from
light, ribosome-poor, slowly translating mRNAs (monosome), ILEI was shown to
be translationally upregulated during EMT (Jechlinger et al., 2003; Waerner et
al., 2006).
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It was previously demonstrated that shRNA-mediated knockdown of Dab2
in NMuMG cells was sufficient to inhibit TGF-mediated EMT as analyzed
morphologically and by loss of upregulation of N-cadherin, a mesenchymal cell
marker (Prunier and Howe, 2005). Re-expression of human Dab2 in Dab2 knockdown cells restored TGF-mediated EMT and N-cadherin up-regulation (Prunier
and Howe, 2005). Also while knockdown of ILEI inhibited TGF-mediated EMT in
EpRas cells (Waerner et al., 2006), ILEI expression caused epithelial plasticity
and tumor formation in NMuMG cells and 3T3 fibroblasts (Waerner et al., 2006).
It can be inferred that both Dab2 and ILEI are necessary, but not sufficient alone
to induce TGF mediated EMT.
It has been shown that post-transcriptional regulation of gene expression
plays an important role in TGF-mediated EMT (Chaudhury et al., 2010). A
novel, 33nt (BAT) structural element has been identified in the 3’-UTRs of Dab2
and ILEI that inhibit translation of the messages, and this inhibition is reversed
following TGFβ treatment of cells (Chaudhury et al., 2010). The 33nt element
forms a 12nt terminal loop separated from an asymmetric bulge by a short 3nt
stem and a proximal 7nt double-helical stem supports the entire structure. This
element was sufficient to mediate translational inhibition of a heterologous
chimeric reporter transcript both in vitro and in vivo. The 3’-UTR BAT element,
was used to affinity purify an mRNP complex that identified hnRNP E1 as a
critical component of the complex (Chaudhury et al., 2010). Prolonged
stimulation of TGFβ released hnRNP E1 from the BAT element allowing their
translation (Chaudhury et al., 2010).
11

It was shown that TGF activates a cascade in which protein kinase
Bβ/Akt2 is activated and subsequently phosphorylates hnRNP E1 at Ser43
residue, culminating in its release from the transcripts and concurrent
translational activation of the two EMT inducers (Chaudhury et al., 2010).
Remarkably, ectopic overexpression of hnRNP E1 in NMuMG cells resulted in
total inhibition of TGFβ-mediated EMT, whereas shRNA-mediated silencing of
hnRNP E1 rendered mesenchymal properties to NMuMG cells irrespective of
TGFβ treatment (Chaudhury et al., 2010). It was also reported that modulation of
hnRNP E1 expression levels or its phosphorylation status modulates migration
and invasive potential in in vitro and in vivo xenograft assays (Chaudhury et al.,
2010). The autocrine response of cells to TGFβ-induced Akt2 activation and
subsequent translational activation of EMT inducer transcripts may represent a
novel mechanism through which the increased TGFβ expression in tumor cells
contributes to cancer progression.
This is the first evidence of isoform specific Akt activation by TGFβ and
Akt2-mediated phosphorylation of hnRNP E1, and confirms recent findings that
Akt2 is involved in promoting EMT, invasiveness and metastasis (Irie et al., 2005;
Chaudhury et al., 2010).
1.6. hnRNP E1: Ubiquitously Expressed, yet Discretely Functional
1.6.1. Origin
Human hnRNP E1 was initially defined as clone sub2.3, having similarity
to hnRNP E2 and containing poly(C) binding activity (Aasheim et al., 1994).
12

hnRNP E1 maps to 2p12-p13 and hnRNP E2 to 12q13.12-q13.13) (Tommerup
and Leffers, 1996). hnRNP E1 and E2 are highly homologous proteins with 82%
amino acid identity. The KH domains in the two are 93% identical. hnRNP E1
was identified as an intronless gene co-expressing with its intron-containing
hnRNP E2 paralog through a series of unique and detailed bioinformatic
analyses (Makeyev et al., 1999). Based on three discrete observations it was
proposed that hnRNP E1 originated via a retrotransposal event that gave rise to
a processed pseudogene, which is surprisingly functional. The evidence being;
(a) hnRNP E1 is intronless (expressed as one exon) but is identical and co-linear
with the hnRNP E2 mRNA (containing multiple exons), (b) hnRNP E1 has only
one loci in the human and mouse genomes, and (c) hnRNP E1 lacks alternatively
spliced forms (Makeyev et al., 1999). It was predicted that hnRNP E1 originated
~400 million years ago, well before the mammalian radiation (Makeyev et al.,
1999), and that it probably acquired a distinct cellular function from hnRNP E2,
allowing for its evolutionary selection. It contains a 31 amino acid auxiliary
domain between KH II and III (Makeyev et al., 1999), which may explain the nonredundant functions and binding specificities of hnRNP E1 and E2. hnRNP E1
has been identified in several murine tissues including bone marrow, liver, heart,
kidney, brain, lung and placenta (Chkheidze et al., 1999; Makeyev et al., 1999)
and is considered to be ubiquitously expressed.
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1.6.2. Structure
hnRNP E1 has 3 KH domains; two are sequestered to the N-terminus,
followed by a non-conserved variable region and a C-terminal KH3 domain. As
mentioned above, KH domains are divided into two subgroups; Type I has a Cterminal βα extension, whereas Type II has a N-terminal αβ extension (Grishin,
2001). hnRNP E1 belongs to the Type I subset (Makeyev and Liebhaber, 2002).
The KH1 and 3 domains have been predicted to bind RNA, whereas the precise
function of KH2 domain is unknown (Leffers et al., 1995; Dejgaard and Leffers,
1996). Specificity for poly(C)-rich binding is postulated to be due to the narrow
binding cleft formed within the KH-domain structure that is accessible only to
smaller pyrimidine bases. Binding is stabilized by formation of hydrogen bonds
between sugar hydroxyl groups of cytosine with the binding cleft in the KHdomain. Since, uracil residues lack these hydroxyl groups, hydrogen bonding
with the KH domain does not occur. This explains comparatively decreased
affinity of KH-domain to poly(U) with respect to poly(C) stretches (Sidiqi et al.,
2005).
1.6.3. Localization of hnRNP E1
Immunofluorescence studies have revealed a predominantly nuclear
localization for hnRNP E1 (Chkheidze and Liebhaber, 2003). Confocal
microscopy showed that hnRNP E1 is sequestered to nuclear speckles, sights of
14

accumulation of splicing factors prior to being loaded on the nascent transcripts.
Hence, hnRNP E1 might have a very prominent role in either loading splice
factors onto nascent transcripts, or functioning as a splicing factor itself (Mintz et
al., 1999; Chkheidze and Liebhaber, 2003). Nuclear localization can be attributed
to a nonameric nuclear localization signal (NLS I), putatively located between
KH2 and KH3 domain, and lacks the NLS II present in hnRNP E2 (Chkheidze
and Liebhaber, 2003). In addition to its nuclear localization, hnRNP E1 has been
observed in the cytoplasm (Gamarnik and Andino, 1997), suggesting that it has
both nuclear and cytoplasmic functions.
1.6.4. hnRNP E1 Functions
1.6.4.1. Transcriptional Activator
hnRNP E1, along with

other hnRNP E proteins, functions as

transcriptional activator of mouse μ-opioid receptor gene (MOR) by binding to a
26 nt cis-acting polypyrimidine stretch within the proximal promoter (Kim et al.,
2005). hnRNP E1 induces MOR mRNA expression by ~4X-folds and siRNAmediated silencing of hnRNP E1 significantly inhibits MOR mRNA expression
(Kim et al., 2005). hnRNP K has been shown to interact with RNA polymerase II
and cause transcriptional upregulation of the c-myc gene (Lynch et al., 2005). It
will be of interest to determine whether hnRNP E1 also interacts with RNA
polymerase II or is mediating its transcriptional effects more indirectly through
binding other transcriptional regulators.
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1.6.4.2. Regulator attenuating alternative splicing
hnRNP E1, in combination with U1 small nuclear RNP, abrogates splicing
of a growth hormone receptor (GHR) pseudoexon implicated in Laron syndrome.
Using RNAi experiments, hnRNP E1 was demonstrated to be a silencer of GHR
pseudoexon expression (Akker et al., 2007). These results corroborated earlier
studies wherein hnRNP E1 was shown to co-localize with the splice factor SC35
in nuclear speckle (Chkheidze and Liebhaber, 2003). In addition, mitogenic
stimulation has recently been reported to promote co-localization of hnRNP E1
with SC35 and alternative splicing and exon inclusion from a CD44-minigene
(Meng et al., 2007).
1.6.4.3. mRNA stability
hnRNP E1 regulates stability of a broad spectrum of mRNAs, including
collagen I and III (Thiele et al., 2004), α-globin (Holcik and Liebhaber, 1997), βglobin (Yu and Russell, 2001), tyrosine hydroxylase (Czyzyk-Krezeska and
Beresh, 1996), erythropoietin (Czyzyk-Krezeska and Bendixen, 1999), androgen
receptor (Yeap et al., 2002), neurofilament-M (NF-M) (Thyagarajan and Szaro,
2004), and renin (Skalweit et al., 2003).
The continuous presence of α-globin mRNA and its translated product is a
pre-requisite during erythropoiesis. Interestingly, α-globin message stability is
regulated by a α-complex binding to a 20 nt CU-rich region in the 3’-UTR of αglobin mRNA (Weiss and Liebhaber, 1994; Holcik and Liebhaber, 1997). The α16

complex is comprised of hnRNP E1, hnRNP E2, hnRNP D (AUF1) and
cytoplasmic poly(A) binding protein (PABP-C) (Kiledjian et al., 1995; Kiledjian et
al., 1997; Chkheidze et al., 1999; Wang et al., 1999; Henics, 2000). Two possible
mechanisms have been proposed by which the α-complex modulates mRNA
stability. PABP-C binds to hnRNP E1/E2 and the poly(A) tail of the α-globin
mRNA and either attenuates deadenylation by inhibiting the deadenylating 3’exonuclease or prevents endoribonucleolytic cleavage by the erythroid enriched
endoribonuclease (ErEN) (Wang et al., 1999; Wang and Kiledjian, 2000a; Wang
and Kiledjian, 2000b; Waggoner and Liebhaber, 2003; Ostareck-Lederer and
Ostareck, 2004) (Fig 1.2). It will be of interest to determine which of the two
pathways is involved in regulating -globin mRNA stability and how it is switchedoff in mature erythrocytes, when α-globin is not required.
1.6.4.4. Translational Regulation
hnRNP E1 has been shown to function as both a translational co-activator
and co-repressor. It functions as an IRES trans-activating factor (ITAF), binding a
stem-loop IV structure in the viral internal ribosome entry site (IRES) element,
and stimulates translation of poliovirus RNA (Gamarnik and Andino, 1997).
Similarly, it stimulates IRES-mediated translation of the Bag-1 (Bcl-2 associated
gene) mRNA (Pickering et al., 2003). On the other hand, hnRNP E1 causes
translational repression

of 15-lipoxygenase

(15-LOX) during erythrocyte

maturation (Ostareck et al., 1997), human papillomavirus type 16 (HPV-16) L2
mRNA (Collier et al., 1998), disabled-2 (Dab2) and interleukin-like EMT inducer
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(ILEI) mRNAs during transforming growth factor-beta (TGFβ)-induced epithelialmesenchymal transition (EMT) (Chaudhury et al., 2010), and A2 response
element containing mRNAs in dendrites within neurons during neuronal
development (Kosturko et al., 2006). In most of the above cases, hnRNP E1
functions with other proteins to induce translational stimulation or repression.
1.6.4.4.1.15-lipoxygenase (15-LOX) mRNA (Fig 1.2): During the process of
erythroid differentiation, the nucleus is compacted and subsequently extruded
from the terminally differentiating erythroblast and thus transcriptional activities
are halted (Najfeld et al., 1988). Thus, subsequent developmental stages are
regulated post-transcriptionally through sequestered mRNP complexes. During
the final stage of erythrocyte maturation, the activation of 15-LOX is required for
mediating mitochondrial degradation. This timely activation of 15-LOX is
achieved by reversal of translational silencing of the 15-LOX mRNA (OstareckLederer and Ostareck, 2004). It has been shown that hnRNP E1 and hnRNP K
bind to a 19 nt CU-rich repeat, the differentiation control element (DICE) in the 3’UTR of the 15-LOX mRNA and inhibit its translation until its activation is required
for completion of differentiation (Ostareck-Lederer et al., 1994; Ostareck et al.,
1997; Ostareck-Lederer et al., 1998). Translational silencing occurs at the
initiation step by preventing 80S complex formation. Specifically, the 60S large
ribosomal subunit is prevented from binding to the 43S pre-initiation complex
(consisting of the 40S small ribosomal subunit, eIF2-GTP, Met-tRNAi, eIF1/1A
and eIF3) at the initiating codon (Ostareck et al., 2001). Activation or reversal of
translational silencing of 15-LOX mRNA is achieved by c-Src-mediated
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phosphorylation of hnRNP K at Tyr 72, 225, 230, 234, 236, and 380.
Phosphorylation disrupts the hnRNP K/E1 mRNP complex from binding to the
DICE elements and thereby relieves translational silencing (Ostareck-Lederer et
al., 2002). Interestingly, hnRNP K activates its kinase, c-Src, through a positive
feedback loop involving translational regulation through its 3’UTR (OstareckLederer et al., 2002). No modification of hnRNP E1 has been reported which
attenuates its binding to the DICE. Of note, there has been one contrasting report
where translational silencing of DICE containing reporter constructs was not
observed in HeLa cells (Kong et al., 2006), even though the cellular context was
not well defined in the reported studies.
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Figure1.2 Post-transcriptional regulation by hnRNP E1 during development
and differentiation.
hnRNP E1 alone, or in combination with other hnRNPs, modulates mRNA
stability of a-globin (A) or the translation of 15-LOX (B) or Dab2 (C) mRNAs. The
regulatory mechanism involves binding to putative cis elements in the 39-UTRs,
which in most cases is disrupted by phosphorylation of one or more of the bound
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hnRNP proteins. A brief description of each regulatory mechanism is given. (15LOX) 15-lipoxygenase; (DICE) differentiation control element; (BAT) TGFbactivated translation element; (Dab2) disabled-2; (ILEI) interleukin-like EMT
inducer.

1.6.4.4.2. HPV-16 L2 mRNA: The capsid proteins, viral latent L1 and L2, of HPV16 are detected only in terminally differentiated human cells, until which time the
expression of L1 and L2 is silenced. hnRNP E1/2 and hnRNP K mediate this
translational inhibition by binding to putative cis-acting inhibitory sequences in the
3’-end of the coding region (Collier et al., 1998). Translational inhibition of L2
mRNAs follows the same recourse as 15-LOX, even though hnRNP E1, hnRNP
K or hnRNP E2 can individually attenuate translation of L2 mRNAs in vitro.
Interestingly, the L2 sequence has only 22% cytosines with no well-defined
poly(C)-repeats, suggesting that hnRNP E1 can preferentially bind to non-poly(C)
regions in mRNA. Earlier work has shown that hnRNP E1 can bind to poly(U)
regions (Leffers et al., 1995), albeit with different affinity.
1.6.4.4.3. Dab2 and ILEI mRNAs (Fig 1.2): Disabled-2 (Dab2) and interleukinlike inducer of EMT (ILEI) are two genes required for transforming growth factor 
(TGF)-mediated epithelial-mesenchymal transition (EMT) (Prunier and Howe,
2005; Waerner et al., 2006). Recently, we have elucidated a novel posttranscriptional regulatory mechanism by which hnRNP E1 silences translation of
Dab2 and ILEI mRNAs (Chaudhury et al., 2010). We identified a novel, 33-nt
structural element in the 3’-UTRs of Dab2 and ILEI that inhibited translation of
their respective mRNAs, an inhibition that was relieved following TGFβ treatment
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of cells. The 33-nt element, called the ‘BAT element’ for TGFbeta activated
translational element, was sufficient to mediate translational inhibition in vitro and
in vivo. Using the BAT element, the mRNP complex (i.e. BAT complex) was
affinity-purified and hnRNP E1 was identified as an integral and functional
component of this complex. TGF activates the protein kinase Akt2, which
subsequently phosphorylates hnRNP E1 at Ser43 residue, culminating in the
disruption of the BAT complex and concurrent reversal of translational silencing
of Dab2 and ILEI mRNAs. Ectopic overexpression of hnRNP E1 in normal mouse
mammary gland (NMuMG) cells prevented the translation of Dab2 and ILEI
mRNAs and the induction of the mesenchymal phenotype in response to TGF.
Conversely, shRNA-mediated silencing of hnRNP E1 resulted in the constitutive
translation of Dab2 and ILEI and of the mesenchymal phenotype irrespective of
TGFβ treatment. Knock-in of a phosphomutant hnRNP E1 (S43A) into the
hnRNP E1 knock-down cells rescued the epithelial phenotype, but not the
sensitivity to TGFβ-induced EMT seen in parental cells, unequivocally showing
the importance of hnRNP E1 phosphorylation for EMT (Chaudhury et al., 2010).
1.6.5. Role of hnRNP E1 in tumorigenesis and cancer progression
It has been suggested that hnRNP proteins, and specifically hnRNP E1,
play a critical and well-defined role in carcinogenesis. The consensus binding site
for hnRNP A1 is UAGGG(A/U), which closely mimics telomeric single stranded
repeats, (TTAGGG)n. In fact, hnRNP E1, A1 and D have been shown to form a
heteromeric complex on telomeric repeats in vitro (Ishikawa et al., 1993)
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suggesting that they may be involved in the maintenance of telomeric length.
This notion is reinforced by the observation that deficient expression of hnRNPs
can cause significant telomere shortening and oncogenic transformation
(LeBranche et al., 1998). Reduced hnRNP E1 expression is also a prerequisite
for human papillomavirus (HPV) proliferation and subsequent incidence of
cervical carcinoma from cervical dysplasia (Pillai et al., 2003). Recently, miR328
has been shown to function as a ‘decoy’ for hnRNP E2. hnRNP E2 binds to cis
element in the 5’-UTR of C/EBPα and inhibit its translation and subsequent
myeloid cell differentiation (Eiring et al., 2010; Beitzinger and Meister, 2010).
miR328 sequesters away hnRNP E2, allowing translation of C/EBPα, which
promotes chronic myelogenous leukemia (CML). Given the sequence similarity
between hnRNP E2 and hnRNP E1, it will be of interest to determine whether
miR328, or a similar miRNA, similarly functions as a decoy for hnRNP E1.
Spreading

initiation

centers

(SICs)

are

defined

ribonucleoprotein

macromolecular complexes, distinct from focal adhesions, and involved in
initiation of cell spreading during cancer metastasis (de Hoog et al., 2004). Using
stable isotope labeling by amino acids in cell culture (SILAC), hnRNP E1, hnRNP
K and the Sm family protein FUS/TLS were identified as intricate constituents of
SICs (de Hoog et al., 2004). Downregulation of hnRNP E1, using neutralizing
antibodies, stimulated cell spreading, consistent with our observation that
shRNA-mediated silencing of hnRNP E1 induces constitutive EMT, another
prerequisite for metastatic progression (de Hoog et al., 2004; Chaudhury et al.,
2010). Finally, two recent reports suggest that hnRNP E1 may be involved in
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controlling embryonic and cancer stem cell proliferation and differentiation. In
nasopharyngeal carcinoma CNE-2 cells (Cao et al., 2010) and in mouse
embryonic stem cells (Baharvand et al., 2008), cellular reprogramming was
associated with a decrease in the expression of hnRNP E1.
1.6.6. How does hnRNP E1 Achieve Functional Diversity?
At the mechanistic level, an interesting question that arises regarding
hnRNP E1, is how are its multifaceted functions mediated. How does it both
regulate translation and stabilize specific mRNAs during differentiation of
hematopoietic cells? In the case of hnRNP K it has been proposed that its
auxiliary domain acts as a docking platform on the RNA that allows it to recruit
and interact with molecules from various signaling pathways (Bomsztyk et al.,
2004). A similar situation can be envisaged for hnRNP E1; however, due to the
non-conserved nature of these auxiliary domains, it is difficult to explain how they
could be mediating conserved or similar functions across different species.
Another model that has been proposed to explain hnRNP E1’s functional
diversity is that it serves as a bridging molecule or ‘chaperone’, on the RNA, that
facilitates the association of proteins in multicomponent regulatory systems,
which in turn render stabilization to secondary nucleic acid structures (OstareckLederer et al., 1998). However, it was subsequently demonstrated that hnRNP E
(hnRNP E2 to be precise) causes mRNA stabilization irrespective of its RNA
binding function, thus questioning the universality of the chaperone model
(Makeyev and Liebhaber, 2002).
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Given its wide ranging functions in the nucleus and cytoplasm and
numerous interacting partners, it is perhaps appropriate to envisage a posttranscriptional regulon model for hnRNP E1’s functional diversity (Keene and
Tenenbaum, 2002). Post-transcriptional regulons involve untranslated sequence
elements for regulation (USER) codes (the 5’- and 3’-UTR cis elements) bound
by well-defined protein complexes that mediate regulatory function (Keene and
Tenenbaum, 2002). Post-transcriptional regulons, operating at different levels of
gene expression, may have evolved as mechanisms to discretely, rapidly and
coordinately suppress multiple genes involved in a regulatory pathway. These
regulons can potentially coordinate overlapping functions temporally in different
cellular locations (Anderson, 2010). Coordinated translational regulation of Dab2
and ILEI mRNAs by TGF indicates that this may constitute a post-transcriptional
BAT regulon inhibiting the expression of related EMT genes (Chaudhury et al.,
2010). Similarly, hnRNP E1 along with hnRNP E2 and hnRNP K associates with
the neurofilament-M (NF-M) mRNA during postnatal development based on the
relative abundance of either the hnRNPs or the NF-M mRNA, is suggestive of a
dynamic post-transcriptional regulon (Thyagarajan and Szaro, 2008).
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Figure 1.3 Post-transcriptional regulons potentiate functional diversity of
hnRNP E1.
Putative cis elements in the 3’-UTRs of target transcripts, untranslated sequence
elements for regulation (USER) codes, determine the content of the mRNP
complex that will form. Many USER codes, such as DICE, BAT, and CARE, have
been defined in mediating posttranscriptional regulation. and one transcript can
harbor more than one USER code. hnRNP E1 and other hnRNPs bind alone or
as a multifactorial mRNP complex to USER codes and give rise to posttranscriptional regulons. This model takes into account the multifunctional,
yet conserved, diversity of hnRNP E1. As shown here, hnRNP E1 binding to
other proteins and specific USER codes, BAT, DICE, or CARE elements, dictates
their subsequent function during differentiation, EMT, and development. (BAT)
TGFb-activated translation element; (DICE)differentiation control element;
(CARE) CACA-rich elements that bind hnRNP L.
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The regulon assembly possibly happens during mRNA processing and
subsequent export to the cytoplasm, in turn pre-deciding the fate of the
transcripts (Moore, 2005). Overall such a model provides a rationale and
energetically favorable framework for integrating functional diversity of hnRNP
E1.
1.6.7. Regulating the Regulator
Considering the cytoplasmic and nuclear functions of hnRNP E1, it can be
assumed that factors controlling its subcellular localization will likely affect its
diverse functions. Earlier studies suggested that the phosphorylation of hnRNP
E1 affects its RNA binding affinity (Leffers et al., 1995); however, only recently
has this been confirmed. p21-activated kinase 1 (Pak1) phosphorylates hnRNP
E1 at Thr60 and 127 residues causing its release from a DICE-minigene and
reversal of translational silencing (Meng et al., 2007). Our recent studies also
clearly demonstrate that phosphorylation of hnRNP E1 by Akt2 at Ser43 residue
causes loss of binding to the BAT RNA element (Chaudhury et al., 2010).
Resolution of the crystal structure of the phosphorylated forms will definitely lead
to a clearer understanding of how post-translational modification attenuates
hnRNP E1’s RNA binding potential. It will also be of interest to determine
whether phosphorylation effects the subcellular localization or half-life of hnRNP
E1. Possibly, RNA binding masks the NLS1 site and prevent nuclear localization
of hnRNP E1, and its phosphorylation and release from the RNA allows the NLS
site to be exposed, thereby promoting nuclear import. Further investigation is
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essential to unravel the signaling pathways regulating hnRNP E1 expression,
turnover and function.
1.7. Ras and EMT
Cancer is characterized by uncontrolled cell growth and the spread of
these abnormal cells (Hanahan and Weinberg, 2000). Over time, carcinogens
induce individual cells to acquire genetic and epigenetic changes in signaling
pathways that regulate their growth and proliferation. These alterations change
normal cells into malignant cells, a process that is referred to as “transformation”.
Transformed cells gain a distinct growth advantage over their neighbors and
subsequently out-compete them for space and nutrients. These cells stop
responding to natural mechanisms of growth regulation and acquire the ability to
proliferate independent of their anchorage. Modified genes that can induce
cellular transformation are known as oncogenes (Croce, 2008) and include
various growth factors, receptor and non-receptor tyrosine kinases, transcription
factors and regulatory GTPases.
Ras genes were originally identified as retroviral oncogenes in the 1960’s
and 70’s following observations that viruses could induce tumor formation in mice
and rats (Chang et al., 1982). The viral genes found to be responsible were
called ras, for rat sarcoma, and turned out to be mutated versions of genes
encoding enzymes with intrinsic GTPase activity. Ras research gained
momentum in the early 1980’s with the discovery of activating Ras mutations in
human tumors (Taparowsky et al., 1982). It was also during the early 1980’s that
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TGF-β was identified as a polypeptide factor secreted from chemically or virally
transformed fibroblasts with the potential to transform normal fibroblasts in
classical in vitro assays (Moses et al., 1981). Soon after its discovery, it was
shown that TGF-β could also act as an inhibitor of cell proliferation (Holley et al.,
1985), thus establishing a dual role for TGF-β in the regulation of cell growth.
Following these observations, it was demonstrated that a relationship exists
between Ras and TGF-β with respect to cellular transformation (Schwarz et al.,
1988), and since then an increasing number of links between Ras and TGF-βsignaling have been identified in the context of cancer progression (Janda et al.,
2002; Oft et al., 1996). Most of the interactions between Ras and TGF-β that
have been described previously have involved prototypic H-Ras, the founding
member of the Ras superfamily. Since its discovery, the Ras superfamily has
grown to over 170 small GTPases (Colicelli, 2004), however, only a small
percentage of these have been shown to act as oncogenes.

1.7.1. The Ras Superfamily of Small GTPases
Ras GTPases are signal-switch molecules that mediate signaling
pathways responsible for a variety of cell functions including growth, adhesion,
migration, cytoskeletal integrity, differentiation and survival (Takai et al., 2001).
These proteins share significant homologies and common motifs, making them
nearly identical in tertiary structure. As enzymes with intrinsic GTPase activity,
Ras proteins are characterized by their capacity to cycle between “active”
guanine triphosphate (GTP)-bound and “inactive” guanine diphosphate (GDP)29

bound conformations. Once GDP is exchanged for GTP, two key regions termed
Switch I and Switch II undergo allosteric changes which alter the configuration of
the so-called effector loop and enable interaction with downstream effectors. This
cycle is illustrated schematically below in Figure 1.4.

Figure 1.4 The Ras GDP-GTP exchange cycle.
Ras is converted from an inactive GDP bound form to an active GTP bound form
through the activity of the guanine nucleotide exchange factors (GEFs). GEFs
promote the exchange of GDP for GTP, while the GTPase activating proteins
(GAPs) catalyze the hydrolysis of GTP to GDP and shift an activated Ras back to
the inactive conformation.
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The activation state of Ras is regulated by the activity of guanine
nucleotide exchange factors (GEFs) which promote the exchange of GDP for
GTP, and by GTPase activating proteins (GAPs) which catalyze the hydrolysis of
GTP to GDP and induce an allosteric shift back to the “inactive” conformation. In
addition to catalyzing the activation of GTPases, GEFs can also determine the
signaling output of the activated GTPase by forming a scaffolding platform for
Ras specific downstream effectors (Buchsbaum et al., 2002). GAPs act by
inserting an “arginine finger” into the GTPase which stabilizes the transition state
of the GTPase reaction, thereby dramatically increasing the hydrolysis rate
(Ahmadian et al., 2003). While Ras effectors are defined as proteins with strong
affinity for GTP-bound Ras and whose binding is impaired by mutations within
the core effector domain, recent observations have shown that GDP-bound Ras
can also interact with several effector proteins and modulate downstream
signaling events. For example, Ras-GDP binds to the transcription factor Aiolos,
thereby modulating the nuclear translocation of Aiolos and the expression of the
anti-apoptotic protein Bcl-2 (Romero et al., 1999).
The normal function of Ras proteins requires them to be posttranslationally modified (Konstantinopoulos et al., 2007). These modifications
serve primarily to localize the proteins to the correct subcellular compartment,
principally the inner face of the plasma membrane. Ras proteins that are
mislocalized within the cell are inactive, most likely because they are unable to
recruit their target enzymes. The fact that correct post-translational modification
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of Ras is required for its biological activity has made the enzymes involved in this
processing very attractive targets for therapeutic intervention (Kloog and Cox,
2004).
Ras family members exhibit a carboxy-terminal CAAX motif, where a
cysteine is followed by two aliphatic residues and one random amino acid. This
motif is targeted for processing by enzymes which results in the addition of a
carboxy-terminal prenyl group. This group, either a farnesyl or a geranylgeranyl
moiety, is involved in anchoring the Ras protein to the plasma membrane. The
specificity for either farnesylation or geranylation is mainly determined by the last
residue of the CAAX sequence (Michaelson et al., 2005). When X is a serine,
methionine, glutamine, alanine or threonine residue the GTPase is farnesylated,
whereas a leucine or phenylalanine residue results in geranylation. Inhibitors of
the enzymes involved in this prenylation process show promise as inhibitors of
Ras function by blocking its localization to the plasma membrane (Martin et al.,
2007).
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Figure 1.5 A comparison of the C-termini of classical Ras proteins
Prenylation alone is insufficient for the functional anchorage of Ras
proteins into the plasma membrane, and additional molecular signals are
required (Laude and Prior, 2008). The nature of these signals dictates the route
by which Ras proteins reach the plasma membrane, and whether they localize to
lipid rafts or to the disordered membrane (Apolloni et al., 2000). One such signal
is palmitoylation, and the carboxy-terminus of H-Ras includes cysteine residues
that undergo further lipid modification by the attachment of palmitoyl moieties
which extend far into the plasma membrane (Dudler and Gelb, 1996). Besides
subcellular localization, both the intensity and the duration of Ras-signaling
profoundly influence downstream signaling networks and the final signal output
(Rocks et al., 2006). The Ras superfamily can be distinguished into six major
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groupings, namely the Ras, Rho, Ran, Rab, Arf and Kir/Rem/Rad families (Takai
et al., 2001). The relations between these groups are represented in

Figure 1.6 The phylogenetic tree of Ras family members.
Of all the Ras family members, the “classical” Ras proteins (H-, K- and NRas) are the best understood. These isoforms share 85% amino acid identity and
are frequently mutated in human tumors (Moon, 2006). Roughly 20% of human
tumors have activating point mutations in Ras, most frequently in K-Ras (about
85% of total), then N-Ras (about 15%), then H-Ras (less than 1%). These
mutations are predominantly located near the bound nucleotide, with codons 12,
13, and 61 being the most common targets (Rajalingam et al., 2007). The effect
of these mutations is to decrease the intrinsic rate of GTP hydrolysis by Ras, and
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to make the Ras protein significantly less sensitive to GAP-stimulated GTP
hydrolysis. Thus, the protein is predominantly in a GTP-bound conformation and
therefore constitutively active.
Oncogenic variants of the classical Ras proteins are capable of
transforming both immortalized rodent fibroblasts and epithelial cells, causing
these cells to appear spindle shaped with disorganized actin filaments, to lose
contact inhibition, and to gain the ability to proliferate independent of anchorage
or in low serum conditions (Moon, 2006). Ras-signaling can also be activated in
tumors by the loss of GAPs (Lee and Stephenson, 2007), or where growth-factor
receptor tyrosine kinases such as EGFR or ERBB2 have been overexpressed
(Higashiyama et al., 2008).

1.7.2. TGF-β and Ras in Cancer
Numerous studies have demonstrated that TGF-β and oncogenic Ras can
act in a cooperative fashion to promote tumorigenesis (Janda et al., 2002a; Kim
et al., 2005; Kretzschmar et al., 1999), yet the mechanisms that underlie this
cooperative behavior are poorly understood. One possibility is that Ras-signaling
negatively regulates Smad activity through phosphorylation of the Smad linker
region. Oncogenic Ras activates the MAPK Erk1/2, and this kinase can directly
phosphorylate specific serine residues in the linker domain of Smad2 and
Smad3, which results in cytoplasmic retention of the Smads and blockage of their
physiological nuclear function (Kretzschmar et al., 1999). This model of linker
phosphorylation has been challenged by a number of independent investigations
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that have analyzed the modulation of Smad-signaling induced by mitogenic
stimuli. In one study, it was demonstrated that linker phosphorylation of Smad 2
and Smad3 by the p38 MAPK and Rho/ROCK pathways was required for the
growth inhibitory effect of TGF-β in human breast cancer cells (Kamaraju and
Roberts, 2005). In a second study, it was found that JNK-dependent
phosphorylation of the Smad2/3 linker region correlated with increased invasion
and metastasis in sporadic colorectal adenocarcinomas (Yamagata et al., 2005).
This observation was supported by a third study which reported that JNKdependent phosphorylation of the Smad2/3 linker region elicited TGF-βdependent tumor growth and invasion in rat gastric epithelial cells (Sekimoto et
al., 2007). These reports suggest that TGF-β-mediated growth inhibition may
require Smad linker phosphorylation, and that oncogenic TGF-β-signaling may
result from the functional collaboration of Ras and Smad rather than from Rasmediated inhibition of the Smad pathway. In addition to these findings, it has
been shown that oncogenic H-Ras can block TGF-β-signaling through MAPKdependent downregulation of Smad4 (Saha et al., 2001). The downregulation of
Smad-signaling activity by oncogenic Ras remains an interesting possibility that
deserves further attention. Additionally, cell type specificity or quantitative
differences in the strength of Ras-signaling between the various systems may
explain the observed discrepancies.
A second possible mechanism underlying cooperative behavior between
TGF-β and Ras involves the abnormal targeting of TGF-β-mediated cell cycle
proteins by oncogenic Ras. For example, it has been reported that oncogenic N36

Ras(K61) can disrupt TGF-β-mediated growth inhibition in epithelial cells through
mislocalization of the cell cycle inhibitor p27 and cyclin dependent kinase (CDK)
6 (Liu et al., 2000). Furthermore, it was shown that leukemia cell lines bearing an
activating mutation in N-Ras (L61) lack a G0-G1 arrest in response to TGF-β due
to a lack of p27, which is targeted for degradation by N-Ras through a MAPKdependent pathway (Schepers et al., 2005). It was also demonstrated that TGFβ-dependent proliferation in U9 colon carcinoma cells requires H-Ras-mediated
downregulation of the cell cycle inhibitor p21cip1 (Yan et al., 2002). One key
event in the TGF-β antiproliferative program is the inhibition of Myc expression
(Orian and Eisenman, 2001), and it was shown that transformation of MCF-10A
human mammary epithelial cells with oncogenic H-Ras results in the loss of the
growth inhibitory response to TGF-β, and that this loss correlates with a loss of
Myc repression (Chen et al., 2001). These data suggest that oncogenic Ras may
block TGF-β-mediated growth inhibition at the level of the cell cycle, either by
sequestering the activity of cell cycle inhibitors such as p27, or by enabling the
proliferative activity of cell cycle proteins such as Myc.
A third possible mechanism of interaction between Ras and TGF-β may lie
at the level of the TGF-β receptor complex itself. Studies in rat intestinal epithelial
(RIE) cells have demonstrated that transformation with oncogenic H-Ras results
in a 5- to 10-fold decrease in mRNA and protein levels of the type II TGF-β
receptor (TBRII) (Bulus et al., 2000). However, studies also show that signaling
through the TBRII is required for H-Ras-induced tumor growth in mammary
epithelial cells (Oft et al., 1998). Taken together, these findings would suggest
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that very few receptors are required to transduce the effects of TGF-β ligand on
Ras-transformed cells. In addition to downregulating TBRII expression,
oncogenic Ras can also stimulate the increased production of TGF-β1 ligand
(Cosgaya and Aranda, 1996). Furthermore, downstream targets of both TGF-β
and Ras-signaling such as JNK (Ventura et al., 2004) and p38 MAPK (Gruden et
al., 2000) also have the ability to regulate TGF-β1 expression levels.
A fourth possible mechanism to explain the cooperative behavior
observed between TGF-β and oncogenic Ras is that they synergistically activate
kinases within signaling pathways mediating cell growth and transformation.
These kinases include Raf (Janda et al., 2006), Erk1/2 (Janda et al., 2002a) ,
JNK (Sekimoto et al., 2007), p38 MAPK (Kim et al., 2005), PI3K (Gotzmann et
al., 2002), Akt (Chen et al., 1998) and mTOR (Lamouille and Derynck, 2007).
Studies have shown that TGF-β and oncogenic H-Ras cooperatively activate
Erk1/2 and PI3Ksignaling in transforming EpH4 cells (Janda et al., 2002a), and
that coordinate activation of Erk1/2 and p38 MAPK is required for TGF-βmediated migration and invasion in H-Ras transformed MCF-10A cells (Kim et
al., 2005). These findings would suggest that stimulation of these growth
promoting pathways by either TGF-β or Ras alone is insufficient to produce a
transformed

phenotype,

while

combined

stimulation

results

in

cellular

transformation. The fact that both Ras have been reported to activate all of the
kinases listed above would suggest that TGF-β may also show cooperative
behavior with these Ras-related GTPases through coordinate activation of
growth promoting signaling pathways.
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CHAPTER II
TGFβ-INDUCED EMT IS REGULATED BY ISOFORM SPECIFIC ACTIVATION
OF AKT2 AND IS RAS DEPENDENT

2.1. Abstract
TGF induces epithelial-mesenchymal transdifferentiation (EMT) accompanied
by cellular differentiation and migration. Our lab has earlier identified a posttranscriptional pathway by which TGF modulates expression of EMT-specific
proteins. It has been shown that heterogeneous nuclear ribonucleoprotein E1
(hnRNP E1) binds a structural, 33 nucleotides (nt) TGF beta-activated translation
(BAT) element in the 3’-UTR of disabled-2 (Dab2) and interleukin-like EMT
inducer (ILEI) transcripts, and repress their translation. The inhibition is removed
following hnRNP E1 phosphorylation by activated Akt2. We now show that
specific activation of Akt2, and not Akt1, following TGF stimulation is Ras
dependent in different EMT model systems.
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2.2. Introduction
Epithelial-mesenchymal transition (EMT), in which cells undergo a switch
from a polarized, epithelial phenotype to a highly motile fibroblastic or
mesenchymal phenotype is fundamental during embryonic development and can
be reactivated in a variety of diseases including fibrosis and cancer (Derynck et
al., 2001; Zavadil and Bottinger, 2005; Bierie and Moses, 2006; Thiery and
Sleeman, 2006; Massague, 2008). TGF is one of the growth factors implicated
in EMT (Massague, 2008). Using normal murine mammary gland epithelial
(NMuMG) cells (Miettinen et al., 1994; Thuault et al., 2006) and mouse mammary
epithelial cells, EpH4, transformed with oncogenic Ras (EpRas) (Oft et al., 1996)
as in vitro models for TGF-induced EMT two candidate EMT genes were
defined, Disabled-2 (Dab2) (Prunier and Howe, 2005) and FAM3C or interleukin
like EMT inducer (ILEI) (Waerner et al., 2006). Dab2 and ILEI are required, but
not sufficient (i.e., in a TGF-independent fashion) to induce EMT. However, the
molecular mechanism by which expression of Dab2 and ILEI is regulated by
TGF remains elusive.
Previous work in our laboratory has shown that post-transcriptional
regulation of gene expression plays an important role in TGF-mediated EMT
(Chaudhury et al., 2010). A novel, 33nt structural element in the 3’-UTRs of Dab2
and ILEI that inhibit translation of the messages has been identified (Chaudhury
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et al., 2010). The 33nt element is sufficient to mediate translational inhibition in
vitro and in vivo (Chaudhury et al., 2010). hnRNP E1 was identified as a critical
component of this complex (Chaudhury et al., 2010). It was shown that TGF
activates a kinase cascade terminating in phosphorylation of Ser43 of hnRNP
E1, by isoform-specific stimulation of protein kinase B/Akt2, inducing its release
from the BAT element and loss of translational silencing of the target mRNAs
(Chaudhury et al., 2010).
We now show that Ras is indispensable for TGFβ-induced EMT.
Overexpression of H-Ras in cells usually resistant to EMT renders them to
change morphology to mesenchymal cells post TGFβ stimulation. Additionally,
we show that Ras is required for isoform specific activation of Akt2 and
subsequent hnRNP E1 phosphorylation.

2.3. Materials and Methods
2.3.1. Reagents.
Mouse -hnRNP E1 was purchased from Novus Biologicals, rabbit hnRNP E1 was from Lifespan Biosciences. -FAM3C and N-Cadherin antibodies
was obtained from Abcam; -E-Cadherin was purchased from BD Biosciences;
-Hsp90 (H-114) antibody and normal mouse and rabbit IgG were purchased
from Santa Cruz Biotechnology. Antibodies against phospho-Akt (Ser-473), total
Akt, Akt1, Akt2, and vimentin were purchased from Cell Signaling Technology. 41

Hsp90 (H-114) and normal mouse and rabbit IgG were purchased from Santa
Cruz Biotechnology.
2.3.2. Cell culture.
TGFβ2 was a generous gift from Genzyme Inc. and was used at a final
concentration of 5 ng/ml. NMuMG cells were cultured as described previously
(Prunier and Howe, 2005). EpH4, EpRas, CCL64 and CCL64Ras were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and antibiotics/antimycotics.
2.3.3. Preparation of cell lysates, immunoblot analysis, and
immunoprecipitation.
For immunoprecipitation and immunoblot analysis, cells were lysed in
buffer D and immunoprecipitation carried out as previously described (Hocevar et
al., 1999).
2.4. Results
2.4.1. NMuMG, EpRas, CCL64Ras cells undergo TGFβ-induced EMT with
concomitant increase in expression of mesenchymal cell markers.
We investigated whether modulating Ras levels altered TGF-mediated
EMT. We used stably overexpressing H-Ras cells (EpRas and CCL64Ras) and
the respective parental cells lines, along with the NMuMG cells, and compared
effects on EMT by phase contrast imaging (Fig. 2.1). NMuMG cells underwent
EMT after TGF treatment (24 hr), while the process was blocked in the EpH4
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and CCL64 cells. Interestingly, the corresponding Ras overexpressing variants
were sensitive to TGFβ-induced EMT. Expression of Dab2, ILEI and
mesenchymal cell markers N-cadherin and vimentin increased concomitantly
with EMT in these cell lines (Fig. 2.2 and data not shown). Parental NMuMG cells
and EpRas and CCL64Ras showed classical mesenchymal cells features
following a 24 hr TGF treatment, including loss of E-cadherin expression, actin
reorganization at cell junctions as evident from the morphological features,
whereas such changes were absent in EpH4 and CCL64 cells, demonstrating
that Ras is an indispensable component of the TGF-mediated EMT
2.4.2. Ras is required for isoform specific activation of Akt2 following TGFβ
stimulation.
To determine whether isoform specific activation of Akt2 was occurring in
the Ras transfected cells, we immunoprecipitated lysates with the Akt isoforms,
Akt1 and Akt2 and probed them with α-p-Akt (pSer473) antibody (Fig. 2.3). TGFβ
selectively activated Akt2 in NMuMG and Ras overexpressing EpRas and
CCL64Ras cell lines, but no activation was observed in EpH4 and CCL64 cells
(Fig. 2.3). The steady state expression of Akt1 and Akt2 though did not change in
these cell lines (Fig. 2.3). Substrate specificity of Akt2 for hnRNP E1 was further
demonstrated by observation of hnRNP E1 phosphorylation only in Ras
expressing cells (Fig. 2.4). The hnRNP E1 phosphorylation kinetics is similar to
TGFβ-mediated phosphorylation of Akt 2. Hence, phosphorylation of hnRNP E1
on Ser43 by TGF-activated Akt2 kinase is Ras dependent.
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Figure 2.1 Ras is required for TGFβ-induced EMT.
Phase contrast images of control and TGF-treated (24 hr) stable (A) NMuMG, (B) EpH4
and (C) EpRas cells were obtained.
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Figure 2.1 TGFβ mediated induction of EMT Markers is observed in NMuMG
and EpRas cells.
NMuMG cells were grown to 80% confluence and stimulated with TGFβ for the indicated
time points. EpRas cells were seeded at a low density such as their final confluence was
around 40-50% after 24h TGFβ treatment at the time of harvesting.
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Figure 2.3 TGFβ mediates isoform specific activation of Akt2 and not Akt1
in Ras containing cell lines.
IB analysis of immunoprecipitates (with α-Akt 1 and Akt2) (top panels) and WCLs
(bottom panels) derived from different model systems treated with TGFβ for the
indicated times.
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Figure 2.4 TGFβ mediated hnRNP E1 phosphorylation in Ras transformed
cells is consistent with Akt2 activation.
IB analysis of WCLs derived from cells post TGF stimulation with α-phospho-serine (pser) antibody. WCLs (right panels) were examined to determine the steady state
expression of hnRNP E1.
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2.5. Discussion
We have identified the indispensability of Ras in the mechanism by which
TGF modulates expression of mRNAs required for EMT, and EMT itself. TGF
activates a kinase cascade terminating in phosphorylation of Ser43 of hnRNP
E1, by isoform-specific stimulation of protein kinase B/Akt2, inducing its release
from the BAT element and loss of translational silencing of Dab2 and ILEI
mRNAs. But a prerequisite for this is the presence of H-Ras.
This is the first evidence of prerequisite of Ras expression for isoform
specific Akt activation by TGFβ and subsequent Akt2-mediated phosphorylation
of hnRNP E1, and confirms recent findings that Akt2 is involved in promoting
EMT, invasiveness and metastasis (Irie et al., 2005).
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CHAPTER III
TGFβ SPECIFICALLY ACTIVATES AKT2 THROUGH A MOLECULAR
COMPLEX INVOLVING FAK AND p85.
3.1. Abstract
TGF

induces

epithelial-mesenchymal

transdifferentiation

(EMT)

accompanied by cellular differentiation and migration. EMT has emerged as a
fundamental

process

governing

embryonic

development,

adult

tissue

homeostasis and metastatic progression. We have earlier shown that Ras is
required for isoform specific activation. Now, we provide evidence which suggest
that Ras mediates a complex formation between activated TGFβ receptors and
ShcA, which in turn potentiates the complex in order to specifically recruit Akt2,
and not Akt1.
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3.2. Introduction
The epithelial-mesenchymal transition (EMT), in which cells undergo a
developmental switch from a polarized, epithelial phenotype to a highly motile
fibroblastic or mesenchymal phenotype, has emerged not only as a fundamental
process during normal embryonic development and in adult tissue homeostasis,
but is also essential for metastatic progression (Derynck et al., 2001; Zavadil et
al., 2005; Thiery et al., 2006). EMT is associated with changes in cell-cell
adhesion, remodeling of extracellular matrix, and enhanced migratory activity, all
properties that enable tumor cells to metastasize (Derynck et al., 2001; Zavadil et
al., 2005; Thiery et al., 2006). Numerous cytokines and autocrine growth factors,
including TGF, have been implicated in EMT (Bierie and Moses, 2006;
Massague, 2008). TGF exerts antiproliferative effects and functions as a tumor
suppressor during early stages of tumorigenesis, whereas at later stages it
functions as a tumor promoter aiding in metastatic progression (Bierie and
Moses, 2006; Massague, 2008). We have earlier shown in Chapter II that
oncogenic Ras is required for TGFβ-mediated EMT and is responsible for the
isoform specific activation of Akt2, the trigger step for the regulatory pathway. But
how Ras renders specificity for Akt2 and not Akt1 activation is not known.
Numerous studies have earlier demonstrated that TGF-β and oncogenic
Ras can act in a cooperative fashion to promote tumorigenesis (Janda et al.,
2002a; Kim et al., 2005; Kretzschmar et al., 1999), yet the mechanisms that
underlie this cooperative behavior are poorly understood. Cell type specificity or
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quantitative differences in the strength of Ras-signaling between the various
systems may explain the observed discrepancies.
A possible mechanism of interaction between Ras and TGF-β may lie at
the level of the TGF-β receptor complex itself. Studies in rat intestinal epithelial
(RIE) cells have demonstrated that transformation with oncogenic H-Ras results
in a 5- to 10-fold decrease in mRNA and protein levels of the type II TGF-β
receptor (TBRII) (Bulus et al., 2000). However, studies also show that signaling
through the TBRII is required for H-Ras-induced tumor growth in mammary
epithelial cells (Oft et al., 1998). Taken together, these findings would suggest
that very few receptors are required to transduce the effects of TGF-β ligand on
Ras-transformed cells. In addition to downregulating TBRII expression,
oncogenic Ras can also stimulate the increased production of TGF-β1 ligand
(Cosgaya and Aranda, 1996). Furthermore, downstream targets of both TGF-β
and Ras-signaling such as JNK (Ventura et al., 2004) and p38 MAPK (Gruden et
al., 2000) also have the ability to regulate TGF-β1 expression levels.
An obvious possible mechanism to explain the cooperative behavior
observed between TGF-β and oncogenic Ras is that they synergistically activate
kinases within signaling pathways mediating cell growth and transformation.
These kinases include Raf (Janda et al., 2006), Erk1/2 (Janda et al., 2002a) ,
JNK (Sekimoto et al., 2007), p38 MAPK (Kim et al., 2005), PI3K (Gotzmann et
al., 2002), Akt (Chen et al., 1998) and mTOR (Lamouille and Derynck, 2007).
Studies have shown that TGF-β and oncogenic H-Ras cooperatively activate
Erk1/2 and PI3Ksignaling in transforming EpH4 cells (Janda et al., 2002a), and
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that coordinate activation of Erk1/2 and p38 MAPK is required for TGF-βmediated migration and invasion in H-Ras transformed MCF-10A cells (Kim et
al., 2005). These findings would suggest that stimulation of these growth
promoting pathways by either TGF-β or Ras alone is insufficient to produce a
transformed

phenotype,

while

combined

stimulation

results

in

cellular

transformation. The fact that both Ras have been reported to activate all of the
kinases listed above would suggest that TGF-β may also show cooperative
behavior with these Ras-related GTPases through coordinate activation of
growth promoting signaling pathways.
Shc adaptor proteins are substrates of receptor tyrosine kinases, and their
phosphorylation initiates signalling events that culminate in Erk activation
(Ravichandran, 2001). Among the three related Shc proteins, ShcA is
ubiquitously expressed, whereas ShcB and ShcC are restricted to cells of neural
origin. ShcA, in turn, is expressed as three isoforms. The prototype p52ShcA
consists of an N-terminal PTB domain followed by CH1 and SH2 domains.
p66ShcA is identical to p52ShcA except for an added N-terminal CH2 domain,
whereas p46ShcA results from N-terminal truncation of the p52ShcA PTB domain.
The PTB and SH2 domains both bind tyrosine-phosphorylated peptides, and
either may associate with activated receptor kinases (Kavanaugh and Williams,
1994). Tyrosine phosphorylation enables p52ShcA to bind the Grb2 adaptor and
the Sos GTP-exchange factor (van der Geer et al., 1996). The ShcA/Grb2/Sos
complex converts Ras into its active GTP-bound form.
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TGFβ Type I receptor (TβRI) and Type II receptor (TβRII) kinase domains
share homologies with tyrosine kinases (Manning et al., 2002), and TβRII
autophosphorylates on tyrosine as well as on serine and threonine (Lawler et al.,
1997). Here we show that Ras potentiates a complex formation between an
SchA, Focal Adhesion Kinase (FAK) and the p85 subunit of PI3K, which recruits
Akt2 and not Akt1. This in turn explains the isoform specific activation of Akt2
following TGFβ stimulation in these cell lines.

3.3. Materials and Methods
3.3.1. Reagents.
Antibodies against Shc-A, phospho-Akt (Ser-473), total Akt, Akt2, and
FAK were purchased from Cell Signaling Technology. -p85/PI3K and p-Tyr
(4G10) were purchased from Upstate Biotechnology; normal mouse and rabbit
IgG were purchased from Santa Cruz Biotechnology.
3.3.2. Cell culture.
TGFβ2 was a generous gift from Genzyme Inc. and was used at a final
concentration of 5 ng/ml. NMuMG cells were cultured as described previously
(Prunier and Howe, 2005). EpH4, EpRas, CCL64 and CCL64Ras were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and antibiotics/antimycotics.
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3.3.3. Preparation of cell lysates, immunoblot analysis, and
immunoprecipitation.
For immunoprecipitation and immunoblot analysis, cells were lysed in
buffer D and immunoprecipitation carried out as previously described (Hocevar et
al., 1999).

3.4. Results
3.4.1. TGFβ rapidly induces tyrosine phosphorylation of ShcA.
TGFβ-induced ShcA tyrosine phosphorylation was assessed in NMuMG
epithelial cells using anti-phosphotyrosine antibodies. TGFβ stimulated rapid
tyrosine phosphorylation of all three isoforms that peaked after 30 minutes (Fig.
3.1, left panel). The rapid ShcA phosphorylation suggested that new gene
expression was not required. This was confirmed by persistent ShcA expression
levels (Fig. 3.1, right panel).
3.4.2. TGFβ induces signalling downstream of ShcA activation
In canonical ShcA signalling, receptor tyrosine kinases phosphorylate
p52ShcA on tyrosine to induce its association with Grb2 and Sos. This heterotrimer
sequentially activates Ras and Raf (Pelicci et al., 1992). Although TGFβ induces
ShcA phosphorylation on serine as well as on tyrosine, our observations along
with others (Lee et al., 2007) suggest that TGFβ activates the ShcA pathway
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through tyrosine phosphorylation. Hence, we next investigated if ShcA
phosphorylation actually recruits focal adhesion kinase (FAK) to the complex.
We evaluated whether TGFβ stimulation enabled ShcA to bind FAK by
stimulating NMuMG cells with TGFβ and immunoprecipitating the endogenous
ShcA at defined times (Fig. 3.2, left panel). The ShcA immunoprecipitates were
then assessed for FAK association by immunoblot analysis. As apparent in Fig.
3.2 (left panel), TGFβ induced ShcA to associate with FAK with kinetics similar to
TGFβ induced ShcA phosphorylation (Fig. 3.1, left panel).
3.4.3. P85 subunit is recruited to the ShcA-RAS-FAK complex that in turn
specifically recruits Akt2.
PI3K activates both Akt1 and Akt2 by recruiting it to the membrane.
P13K has a p110 catalytic subunit and the p85 subunit which essentially
functions as the anchor for the PI3K to the membrane and downstream signaling
molecules. N- and C-terminal SH2 domains of p85 had preferential binding
affinities for FAK (Sanchez-Margalet et al., 1995). Hence, we hypothesized that
the Ras-FAK-ShcA complex might interact with p85 subunit, which might render
specificity for Akt activation.
We evaluated whether TGFβ stimulation enabled ShcA-FAK-Ras complex
by stimulating NMuMG cells with TGFβ and immunoprecipitating the endogenous
ShcA at defined times (Fig. 3.3, left panel). The ShcA immunoprecipitates were
then assessed for p85 subunit association by immunoblot analysis. As apparent
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in Fig. 3.3 (left panel), TGFβ induced p85 subunit of PI3K to associate with the
complex with kinetics similar to TGFβ induced ShcA phosphorylation (Fig. 3.1,
left panel). Additionally, we observed that only Akt2, and not Akt1, is recruited to
this heteromeric complex (Fig. 3.4, right panel and data not shown), which
explains the subsequent association seen of p-Akt with this complex (Fig. 3.4, left
panel).

Figure 3.1 TGFβ induces Shc tyrosine phosphorylation.
Anti-phosphotyrosine immunoblot of ShcA immunoprecipitated from lysates of NMuMG
cells treated with 5 ng/ml TGFβ for the indicated times (left panel), together with ShcA
immunoblots of the same membranes (right panel).
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Figure 3.2 TGFβ induces recruitment of FAK to ShcA.
Anti-FAK immunoblot of ShcA immunoprecipitated from lysates of NMuMG cells treated
with 5 ng/ml TGFβ for the indicated times (left panel); immunoblot analysis of FAK from
lysates of NMuMG cells treated with 5 ng/ml TGFβ for the indicated times (right panel).

Figure 3.3 ShcA interacts with p85 subunit through FAK.
Anti-p85/PI3K immunoblot of ShcA immunoprecipitated from lysates of NMuMG cells
treated with 5 ng/ml TGFβ for the indicated times (left panel); immunoblot analysis of
p85/PI3K from lysates of NMuMG cells treated with 5 ng/ml TGFβ for the indicated times
(right panel).
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Figure 3.4 TGFβ induces preferential recruitment and activation of Akt2.
Anti-P-Akt (left panel) and Akt2 (right panel) immunoblot of ShcA immunoprecipitated
from lysates of NMuMG cells treated with 5 ng/ml TGFβ for the indicated times.
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3.5. Discussion
We have identified the underlying mechanism responsible for isoform
specific activation of Akt2 post TGFβ stimulation, which in turn modulates
expression of mRNAs required for EMT, and EMT itself. TGF activates
activation of ShcA, which in turn recruits FAK, Ras and finally p85 subunit. Akt2
is selectively recruited to this complex and phosphorylated.
It has been shown that receptor tyrosine kinases initiate ShcA signalling
by phosphorylating p52ShcA at tyrosines 239, 240, and 317 (van der Geer et al.,
1996), thereby creating binding sites for Grb2. The resulting ShcA/Grb2/Sos
complex then translocates to the plasma membrane and activates Ras (Lotti et
al., 1996). Similarly, TGFβ induces low levels of ShcA/Grb2 association that
correlate with low levels of downstream signaling activation, suggesting that the
same tyrosines mediate TGFβ signalling.
Thus it might be possible to target any member of this novel complex for
designing therapeutics to target tumor progression.
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CHAPTER IV
SUMMARY AND PERSPECTIVE

We have identified a mechanism for isoform specific activation of Akt2
following TGFβ stimulation. This adds to the knowledge of what our lab has
previously shown regarding the transcript-selective translational regulation
pathway by which TGF modulates expression of mRNAs required for EMT, and
EMT itself in vitro and tumorigenesis and metastasis in vivo. TGFβ activates
ShcA, which then in a cascade reaction recruits FAK, Ras, p85 and finally Akt2.
This terminates in phosphorylation of Ser43 of hnRNP E1, by isoform-specific
stimulation of protein kinase B/Akt2, inducing its release from the BAT element
and loss of translational silencing of the target mRNAs.
Recently, it has been shown that a feedback loop exists between Akt and
hnRNP E1 whereby the activation of Akt can be regulated by hnRNP E1. It will
be interesting to determine if the loop also functions in an isoform-dependent
fashion. Given our observations, it might be hypothesized that such feedback
regulation will not be ubiquitous and in fact is the cell’s way of introducing fidelity
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and fine tuning into the whole EMT pathway. The autocrine response of
cells to TGFβ-induced Akt2 activation, and subsequent translational activation of
transcripts involved in EMT, may represent a mechanism by which increased
TGFβ expression in tumor cells contributes to cancer progression and provides
new avenues for novel anti-cancer therapeutic designs.
Rigorous investigation leading to the identification of the other
components of the complex will also answer in details why Akt1 is not recruited
and will surely be one of the avenues of future research. Future work will also
delve into finding small molecules that will selectively inhibit the complex
formation during secondary cancer progression.
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